Summary Suppression of the secretion of prolactin, growth hormone and insulin-like growth factor 1 (IGF-1) might be important in the growth regulation and treatment of breast cancer. Because oestrogens may counteract the anti-tumour effects of such treatment, the combination of an anti-oestrogen (tamoxifen), a somatostatin analogue (octreotide) and a potent anti-prolactin (CV 205-502) might be attractive. In this respect, we performed a first exploratory long-term study on the feasibility of combined treatment and possible clear differences in endocrine and anti-tumour effects during such combined treatment vs standard treatment with tamoxifen alone. Twenty-two post-menopausal patients with metastatic breast cancer (ER and/or PR positive or unknown) were randomized to receive either 40 mg of tamoxifen per day or the combination of 40 mg of tamoxifen plus 75 ig of CV 205-502 orally plus 3 x 0.2 mg of octreotide s.c. as first-line endocrine therapy. An objective response was found in 36% of the patients treated with tamoxifen alone and in 55% of the patients treated with combination therapy. Median time to progression was 33 weeks for patients treated with tamoxifen and 84 weeks for patients treated with combination therapy, but the numbers are too small for hard conclusions. There was no difference in overall post-relapse survival between the two treatment arms. With respect to the endocrine parameters, there was a significant decrease of plasma IGF-1 levels in both treatment arms, whereas during combined treatment plasma growth hormone tended to decrease and plasma prolactin levels were strongly suppressed; in some patients insulin and transforming growth factor a (TGF-a) decreased during the triple therapy. Although there was no significant difference in mean decrease of plasma IGF-1 levels between the two treatment arms, combined treatment resulted in a more uniform suppression of IGF-1. Therefore, the addition of a somatostatin analogue and an anti-prolactin may potentially enhance the efficacy of anti-oestrogens in the treatment of breast cancer owing to favourable endocrine and possible direct anti-tumour effects. Large phase IlIl trials using depot formulations (to increase the feasibility) of somatostatin analogues are warranted to demonstrate the potential extra beneficial anti-tumour effects of such combination therapy.
Different steroid hormones, peptide hormones, growth factors and other trophic substances are involved in the growth regulation of human breast cancer (Clarke et al, 1992; Klijn et al, 1992) . Oestrogens, especially oestradiol, are the most potent growth stimulatory hormones of breast cancer. Therefore, endocrine treatment of metastatic breast cancer usually uses antisteroidal agents such as tamoxifen, resulting in response rates of 30-40% (Santen et al, 1990) .
Together with oestradiol, insulin-like growth factors (IGF-l and IGF-2) are the most potent mitogens for breast cancer cells (Osborne et al, 1990; Clarke et al, 1992; Cullen et al, 1992) . The growth effects of both are mediated predominantly via IGF-1 receptors, which have been demonstrated in 67-93% of primary human breast cancers (Pekonen et al, 1988; Peyrat et al, 1988a; Foekens et al, 1989a; Klijn et al, 1993) at higher density than in normal or benign breast tissue (Peyrat et al, 1988b) . In vivo, pituitary-derived growth hormone (GH) regulates endocrinologically the secretion of IGF-1 (Kelly et al, 1991; Lamberts et al, 1991) , but possibly also has regulatory effects on local IGF-1 secretion within (tumour) tissues (Davoren et al, 1986; Schally et al, 1987; Kelly et al, 1991) . In addition, in breast cancer local production of GH with a potential paracrine function has been described (Mol et al, 1995) . In vitro, physiological concentrations of the lactotrophic hormones GH and prolactin (PRL) can stimulate the growth of breast cancer cells (Malarkey et al, 1983; Murphy et al, 1984; Manni et al, 1986; Bonneterre et al, 1990) . In primary human breast cancers, receptors for these lactotrophic hormones have been demonstrated in 13-72% of series of tumours investigated depending on the techniques used (Bonneterre et al, 1990) . Furthermore, increased plasma levels of both GH (Emerman et al, 1985) and PRL (Holtkamp et al, 1984; Emerman et al, 1985) as well as of IGF-1 (Peyrat et al, 1993) (Schally et al, 1987; Schally et al, 1988; Manni et al, 1989 , Pollak et al, 1989 Lamberts et al, 1991; Lamberts et al, 1996) . Interestingly, receptors for somatostatin (SSTR) have also been demonstrated in 36-67% of primary human breast cancers (Reubi et al, 1990; Fekete et al, 1989; Klijn et al, 1992; and in even 75% by in vivo receptor scintigraphy (Van Eijck et al, 1994) , indicating that somatostatin analogues can directly affect tumour growth. Indeed, we (SetyonoHan et al, 1987) and others have previously shown (Lamberts et al, 1991; Weckbecker et al, 1992 ) direct growth-inhibitory effects of somatostatin analogues on human breast cancer cell lines.
Based on the data mentioned above, it can be concluded that somatostatin analogues and antiprolactins can have beneficial direct and indirect effects on the treatment of breast cancer. However, until now a single treatment with these agents showed only minor activity in post-menopausal patients with metastatic breast cancer (European Breast Group, 1972; Minton et al, 1974; Engelsman et al, 1975; Grisoli et al, 1981; Morten et al, 1988; Manni et al, 1989; Vennin et al, 1989; Holtkamp et al, 1990; Klijn et al, 1992) . Because unopposed oestrogen action can overrule the growth inhibitory effects of somatostatin analogues (Setyono-Han et al, 1987) and/or anti-prolactions, combination treatment With an anti-oestrogen, a somatostatin analogue and an anti-prolactin might be of value and may increase the efficacy of single treatment with tamoxifen alone. As tamoxifen affects growth factor secretion (Coletti et al, 1989; Pollak et al, 1990; Clarke et al, 1992; Kiang et al, 1992; Lonning et al, 1992; Reed et al, 1992; Winston et al, 1994) Currently, the mean follow-up of all 20 evaluable patients is 3 years (range 3 months-6 years). Within this follow-up period all but two patients showed progressive disease and 14 died. The patients were randomized to be treated with either tamoxifen 40 mg per day or with the combination treatment consisting of 40 mg of tamoxifen, 75 ,ug of the dopamine agonist CV 205-502 (Norprolac) and the somatostatin analogue octreotide (Sandostatin) 200 mg t.i.d. subcutaneously every day. Dose modification was not allowed. The duration of treatment varied from 6 weeks to more than 6 years. Patients were evaluated for toxicity and response every 6-12 weeks. Measurements of tumour response were performed according to the UICC criteria.
Plasma samples for measurement of basal hormone and growth factor concentrations (Table 2) were taken before and regularly between 4-24 weeks after start of treatment ( Figure 1 ). Plasma peptide hormones and growth factors were measured by radioimmunoassays and radioreceptor assay (TGF-a), as described previously (Klijn et al, 1990a) . Plasma oestradiol levels were measured by radioimmunoassay.
Statistical methods
The expected accrual rate per year was 60 patients. Because of a much lower actual recruitment, in particular because of the refusal of daily injections in the combined treatment arm, the trial was closed after the inclusion of 22 patients in 2 years. Because of the relatively low number of patients in this study, the analysis of the data has been primarily descriptive, directed at the calculation of response rate, progression-free survival with actuarial methods and a description of the endocrine effects of the treatments by calculating the change in plasma concentration levels from the baseline. Because of the limited power of this study to detect differences between treatment arms, all P-values reported in this (Figure 1 ), but in view of differences in pretreatment values and a large variation during treatment there was only a trend for a difference (P = 0.10) between the two treatment arms (Table 2) . Most interesting was the significant decrease (P < 0.0002) of plasma IGF-l levels during treatment (Figure 1 ), i.e.
overall a mean decrease of 49% during combined treatment and 38% during single treatment with tamoxifen. This decrease showed no significant difference between the two treatment groups, either absolutely (P = 0.63, Table 2 ) and percentually (P = 0.21). However, IGF-1 suppression was more uniform during combined treatment in contrast to a strong variation in response during tamoxifen treatment (Figure 1 ). In plasma prolactin levels, the combined treatment caused a clearly significant suppression of prolactin secretion owing to the antiprolactin CV 205-502, whereas tamoxifen had no significant effect ( Figure 1 , Table 2 , P = 0.006).
In the other endocrine parameters, some patients showed a decrease of plasma insulin and TGF-x levels during combined treatment (Figure 1 ), but differences in overall results between the two treatment arms (Table 2) were only found for insulin (P = 0.02) and not for TGF-a (P = 0.11).
Anti-tumour effects
Five (55%) out of nine patients treated with the combination therapy showed an objective response compared with 4 (36%) out of 11 patients treated with tamoxifen alone (Table 3 ). The median time to progression was 84 weeks for the patients treated with combination therapy vs 32 weeks for patients treated with tamoxifen. Progression-free survival was slightly better for patients treated with the combination of drugs than those treated with British Journal of Cancer (1998) (Pekonen et al, 1988; Peyr, Foekens et al, 1989a; Bonneterre et al, 1990; Cl Klijn et al, 1993) , have been demonstrated in al tumours and/or human primary breast cancers suggesting a role in autocrine/paracrine cell growth regulation. However, nearly all endocrine therapies are focused on antagonism of oestradiol, the primary mitogen for human breast cancer (Santen et al, 1990 ). Some trials have tested the value of suppression of prolactin secretion by dopamine agonists (antiprolactins) (European Breast
Cancer Group et al, 1972; Minton et al, 1974; Engelsman et al, 1975; Grisoli et al, 1981; Fentimen et al, 1988; Morten et al, 1988; Manni et al, 1989; Holtkamp et al, 1990) . Initial trials using single dopaminergic treatment with L-dopa or bromocriptine showed poor results (European Breast Cancer Group et al, 1972; Minton et al, nation treatment 1974; Engelsman et al, 1975; Grisoli et al, 1981) . Two studies investigated combination therapy of bromocriptine with antister--1 oidal treatment. Dogliotti et al (1987) (1988) observed no additional anti-tumour effect of bromocriptine to tamoxifen. This might be explained by the facts that progestins can ie two treatment increase plasma PRL levels (Alexieva-Figusch et al, 1984) , whereas tamoxifen has rather inhibitory effects on PRL secretion (Klijn et al, 1985; Lamberts et al, 1990; Malaab et al, 1992) . Other authors (Manni et al, 1989; Bonneterre et al, 1990; Pollak et al, 1992) assumed that the lack of anti-tumour effects by single dopaminergic treatment may have been due to the presence of hGH, which is also ents in this feasia lactogen and can bind to lactotrophic receptors (Bonneterre et al,
ns. There was no 1990). However, a few pilot studies using combined treatment with espect to overall bromocriptine and a GH-lowering drug, such as a somatostatin analogue, showed no impressive effects in heavily pretreated patients with metastatic breast cancer (Morten et al, 1988; Manni et al, 1989; Holtkamp et al, 1990; Klijn et al, 1992 al, 1991, 1996) . This interest was further increased by the detecbut no serious tion of SSTRs in breast cancer cell lines and tissues (Setyono-Han es mellitus had a et al, Srkalovic et al, 1990; Weckbecker et al, 1992 ; Prevost )mbined therapy et al, Buscail et al, 1995) and in about half of primary breast iaybe as a consecancers (Fekete et al, 1989; Reubi et al, 1990; Van Eijck et al, octreotide) . . Indeed, we (Setyono-Han et al, 1987) and others (Lamberts of asymptomatic et al, 1991; Weckbecker et al, 1992) have demonstrated direct bination therapy.
growth-inhibitory effects by various somatostatin analogues on different breast cancer cell lines. Inhibition of cell proliferation seems to be mediated especially by subtypes SSTR2 and SSTR5 (Buscail et al, 1995; Lamberts et al, 1996) . In addition, in some levelopment and experimental animal models somatostatin analogues were able to understood. All cause inhibition of mammary tumour growth (Rose et al, 1983 ; 1 in plasma from Schally et al, 1987 from Schally et al, , 1988 Szende et al, 1989; Weber et al, 1989; (Holtkamp et al, Lamberts et al, 1991; Weckbecker et al, 1994; Lamberts et al, Growth stimula-1996) . However, in four clinical studies (Morten et al, 1988 ; n be blocked by Manni et al, 1989; Vennin et al, 1989; Holtkamp et al, 1990) (Klijn et al, 1992) . In addition, in previously untreated Mol et al, 1995) patients single first-line treatment with octreotide appeared to be at et al, 1988a; less effective than common standard treatment modalities, which arke et al, 1992; resulted in early stopping of this treatment arm in an on-going nimal mammary randomized trial of the Mayo Clinics.
British Journal of Cancer (1998) These disappointing results of single somatostatin analogue treatment (or in combination with an anti-prolactin) can be explained by our observation that oestradiol abolished these growth inhibitory effects (Setyono-Han et al, 1987) . Therefore, at the start of the present clinical study in 1989 our study design testing these drugs in combination with an anti-oestrogen seems to be more appropriate. Later on, this approach was supported by the results of different preclinical studies that showed the additive biological (Huynh et al, 1994) and anti-tumour effects (Weckbecker et al, 1994; Bogden et al, 1995) of somatostatin analogues to endocrine therapy with tamoxifen or by surgical oophorectomy in hormone sensitive tumours in vivo. Meanwhile, tamoxifen appeared not only to act by blocking the growth stimulatory effects of oestrogens but also to modify growth factor secretion (Coletti et al, 1989; Pollak et al, 1990; Butta et al, 1992; Clarke et al, 1992; Kiang et al, 1992; Lonning et al, 1992; Reed et al, 1992; Huynh et al, 1994; Winston et al, 1994; Kopp et al, 1995; Van Roozendaal et al, 1995) and to suppress the GH/IGF-I axis (Malaab et al, 1992; Pollak et al, 1992; Tannenbaum et al, 1992) and prolactin secretion (Klijn et al, 1985; , Malaab et al, 1992 . Tamoxifen and other antioestrogens can decrease plasma IGF-1-levels (Coletti et al, 1989; Pollak et al, 1990; Kiang et al, 1992; Lonning et al, 1992; Reed et al, 1992; Winston et al, 1994) , but also can down-regulate IGF-I-R (Freiss et al, 1990 ) and can suppress IGF-1-induced breast cancer cell proliferation (Pratt et al, 1993) . Furthermore, both octreotide (Lamberts et al, 1991) and anti-oestrogens (Loning et al, 1992; Reed et al, 1992; Pratt et al, 1993; Winston et al, 1994) affect IGF-binding proteins. Thus, additive endocrine and antitumour effects could be expected from combination therapy with tamoxifen plus a somatostatin analogue and an anti-prolactin. In our study, tamoxifen caused an increase rather than a decrease in basal GH concentrations. In contrast, in several patients combination treatment tended to decrease basal GH levels. Previously, Pollak et al (1989) and Manni et al (1989) showed significant suppression of stimulated GH-levels (which are less affected by fluctuation than basal plasma GH levels during the day) by octreotide treatment. In contrast to the basal GH concentration, IGF-I levels are stable during the day. Strikingly, we found no additive suppressive effects of tamoxifen and octreotide on mean plasma IGF-1 concentrations, but combination treatment caused a more uniform suppression of IGF-1 (Figure 1 ). Both single tamoxifen and combination treatment caused a decrease of about 40-50%. This might partly be explained by the observation that tamoxifen already increases the release of endogenous hypothalamic somatostatin, resulting in blunting of pituitary GH pulse amplitude (Tannenbaum et al, 1992) . However, this does not exclude that clear additive endocrine effects might be found in studies using lower dosages of tamoxifen (20 instead of 40 mg day-') or higher dosages of somatostatin analogues than used in our trial. Recently, Kiang et al (1992) reported an interesting observation indicating that the type of anti-tumour response is related to the extent of IGF-I suppression. In our study, we were not able to confirm this observation.
In basal plasma insulin and TGF-a concentrations, we found no impressive differences between the two treatment arms, although the combination therapy had a suppressive effects in some patients. Although somatostatin analogues might affect LH secretion in premenopausal patients (Chiodera et al, 1986) , in our postmenopausal patients no significant effects on plasma E2 levels were observed. This finding confirms the results of the study of Manni et al (1989) who also found no effect of combined octreotide/bromocriptine treatment on plasma LH, FSH and E2 levels. Finally, with respect to prolactin secretion (which is partly influenced by oestrogens) the anti-oestrogen tamoxifen tended to decrease plasma PRL levels, although not significantly. Interestingly, the new very potent antidopaminergic drug CV 205-502 used in the treatment of prolactinomas (Rasmussen et al, 1987) caused a strong significant decrease of basal prolactin levels (with about 70%) in our patients with normal PRL secretion. This suppression is more pronounced than previously reported for bromocriptine. However, in contrast to oestradiol, it is currently unknown to which plasma levels PRL has to be suppressed to contribute to an (potential) extra anti-tumour effect.
With respect to the performance of our study, the triple endocrine therapy appeared to be feasible in the presence of only few non-serious side-effects. However, a significant number (40-50%) of potentially eligible patients refused participation in the trial because of the need of three daily injections in one of the treatment arms. This problem will be resolved by the application of depot preparations of somatostatin analogues that are increasingly available. Furthermore continuous administration of drugs is generally more effective than daily injections as demonstrated for octreotide (Klijn et al, 1990b; Weckbecker et al, 1994 ). In our pilot study, the patients treated with the combination therapy showed progressive disease from start of treatment less frequently and a longer progression-free survival, but the numbers are undoubtedly too small for definite conclusions and our results have to be confirmed by other much larger studies.
In conclusion, the results of different preclinical studies indicate that the addition of a somatostatin analogue (with or without combination with an antiprolactin) may enhance the anti-tumour efficacy of anti-oestrogens in the treatment of breast cancer (Huynh et al, 1994; Weckbecker et al, 1994; Bogden et al, 1995) . Our first randomized clinical study on triple therapy showed that in principle such an approach is clinically feasible and caused significant endocrine effects. A large multicentre randomized study in metastatic breast cancer, using a depot preparation of octreotide instead of daily injections, is warranted (and on-going) to prove the presence of such potential extra beneficial anti-tumour effect.
